Answers are grounded in this paper and cite their sources.
This study focuses on the design, synthesis, and comprehensive biological evaluation of novel quinazoline derivatives as potential therapeutic agents. The structures of nine synthesized compounds were confirmed using spectral methods such as infrared (IR), proton nuclear magnetic resonance (1H NMR) spectroscopy, and elemental analysis. These compounds were assessed for antimicrobial, antioxidant, and anticancer activities against human cancer cell lines including hepatocellular carcinoma (HepG-2), breast cancer (MCF-7), and colorectal carcinoma (HCT-116). Among them, Compounds 8 and 9 exhibited remarkable biological activities. Both compounds demonstrated significant antimicrobial and antioxidant effects, alongside potent antiproliferative activity against (HepG-2), breast cancer (MCF-7) and colorectal carcinoma (HCT-116) cell lines. Notably, Compound 8 showed superior cytotoxicity with IC50 values of 30.81, 53.41, and 76.73 µM against HepG-2, MCF-7, and HCT-116 cells, respectively, outperforming Compound 9. Molecular docking studies corroborated these results, revealing strong binding affinities of Compounds 8 and 9 to key protein targets implicated in antimicrobial and anticancer mechanisms, including Escherichia coli DNA gyrase, Staphylococcus aureus dihydropteroate synthase (DHPS), CDK2 and EGFR. Furthermore, in-silico ADMET predictions indicated favorable drug-likeness and low toxicity risks, aligning with Pfizer’s drug design guidelines. Overall, Compounds 8 and 9 emerge as promising leads with broad-spectrum therapeutic potential for pharmaceutical and food industry applications.
No takes yet. Share an insight, caveat, or question.
Zaki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: